Gilead's new CEO will be facing many challenges — here's what he might do, and why Wall Street is mostly optimistic (GILD, RHHBY)

9:47am PST - December 10th, 2018    john wall - Business Insider

Roche veteran Daniel O'Day will take over as CEO of Gilead Sciences next year. Wall Street is hoping O'Day will put Gilead's cash to work in big deals, but some note his deal track record is limited. Gilead's flagging pipeline of drugs will need to be a top p…